白蛋白结合型紫杉醇联合替吉奥一线治疗晚期胃癌的回顾性分析  

A Retrospective Analysis of Abraxane Combined with S-1 as First-line Treatment for Advanced Gastric Cancer

作　　者：方科 张战民[1] FANG Ke;ZHANG Zhanmin(The First Affiliated Hospital of Nanchang University Gaoxin Campus,Nanchang 330100,China)

机构地区：[1]南昌大学第一附属医院高新医院,江西南昌330100

出　　处：《中国医学创新》2020年第7期40-44,共5页Medical Innovation of China

摘　　要：目的:探讨白蛋白结合型紫杉醇联合替吉奥在晚期胃癌一线治疗中效果及安全性。方法:回顾性分析本院2017年1月-2018年8月65例晚期胃癌患者的临床资料。按照一线治疗方案不同分为治疗组(n=33)与对照组(n=32)。治疗组应用白蛋白结合型紫杉醇联合替吉奥方案化疗。对照组应用奥沙利铂联合替吉奥方案化疗。比较两组缓解率、疾病控制率、中位无疾病进展时间(median progression-free,mPFS)、中位生存时间(median overall survival,mOS)及不良反应情况。结果:两组缓解率比较,差异无统计学意义(P>0.05),治疗组疾病控制率高于对照组(P<0.05)。治疗组mPFS为7.26个月,mOS为12.93个月;对照组mPFS为5.20个月,mOS为10.11个月。治疗组无疾病进展时间(PFS)和生存时间(OS)均优于对照组(P<0.05)。两组Ⅲ级和Ⅳ级不良反应发生率比较,差异无统计学意义(P>0.05)。结论:白蛋白结合型紫杉醇联合替吉奥一线治疗晚期胃癌效果显著,未增加不良反应发生率,安全性好,值得临床推广使用。Objective:To investigate the efficacy and safety of Abraxane combined with S-1 in the first-line treatment of advanced gastric cancer.Method:The clinical data of 65 patients with advanced gastric cancer in our hospital from January 2017 to August 2018 were retrospectively analyzed.According to the first-line treatment plan,they were divided into treatment group(n=33)and control group(n=32).The treatment group was treated with Abraxane combined with S-1 chemotherapy.The control group was treated with Oxaliplatin combined with S-1 chemotherapy.The remission rate,disease control rate,median progression-free(mPFS),median overall survival(mOS)and adverse reactions in the two groups were compared.Result:There was no significant difference in the remission rate between the two groups(P>0.05).The disease control rate of the treatment group was higher than that of the control group(P<0.05).The mPFS was 7.26 months and the mOS was 12.93 months in the treatment group.The mPFS was 5.20 months and the mOS was 10.11 months in the control group.The progression-free(PFS)and overall survival(OS)in the treatment group were better than those in the control group(P<0.05).There was no significant difference in incidence ofⅢandⅣadverse reactions between the two groups(P>0.05).Conclusion:Abraxane combined with S-1 has a significant effect in the first-line treatment of advanced gastric cancer,with no increase in the incidence of adverse reactions,has good safety.It is worthy of clinical promotion.

关 键 词：白蛋白结合型紫杉醇 替吉奥 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]